Sugi Predict

Sugi Predict / Compounds / SCHEMBL505673

SCHEMBL505673

SCHEMBL505673

NCCNCCNCCNOC(=O)CCC(=O)ONCCNCCNCCN

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.46
▸ CA6 P23280 4/20 0.46
▸ CA7 P43166 4/20 0.46
▸ CA9 Q16790 4/20 0.46
▸ CA14 Q9ULX7 4/20 0.46
▸ CA5B Q9Y2D0 4/20 0.46
▸ LMNA P02545 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA4 P22748 3/20 0.46
▸ CA5A P35218 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ CA3 P07451 2/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ CA1 P00915 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.44
▸ MEN1 O00255 2/20 0.42
▸ RECQL P46063 2/20 0.42
▸ KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449733 1.00 CA12 (0.46) CA12CA6CA7CA9CA14
SCHEMBL7530475 0.94 CA12 (0.44) CA12CA6CA7CA9CA14
SCHEMBL2449939 0.94 CA12 (0.44) CA12CA6CA7CA9CA14
SCHEMBL11876120 0.94 CA12 (0.44) CA12CA6CA7CA9CA14
SCHEMBL11871563 0.92 CNR2 (0.44) CA12CA6CA7CA9CA14
SCHEMBL11875752 0.92 CNR2 (0.44) CA12CA6CA7CA9CA14
SCHEMBL11874416 0.92 CNR2 (0.44) CA12CA6CA7CA9CA14
SCHEMBL11878245 0.92 CNR2 (0.44) CA12CA6CA7CA9CA14
SCHEMBL11878042 0.89 CA12 (0.48) CA12CA6CA7CA9CA14
SCHEMBL27777327 0.87 NFKB1 (0.45) CA12CA6CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017213524-A1 TREATMENT OF NEURODEGENERATIVE DISORDERS COOPER GARTH (NZ) 2017-12-14 — — WO claimed
US-20150196500-A1 Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits PHILERA NEW ZEALAND LIMITED (NZ) 2015-07-16 — — US claimed
US-20130108709-A1 TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS PROTEMIX CORPORATION LIMITED (NZ) 2013-05-02 — — US claimed
US-20100160428-A1 TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS PROTEMIX CORPORATION LIMITED (NZ) 2010-06-24 — — US claimed
US-20090093542-A1 Copper antagonist compositions COOPER GARTH J S 2009-04-09 — — US claimed
US-20090093506-A1 Copper antagonist compositions COOPER GARTH J S 2009-04-09 — — US claimed
EP-1948160-A1 TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS Protemix Corporation Limited (NZ) 2008-07-30 — — EP claimed
WO-2007055598-A1 TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS PROTEMIX CORPORATION LIMITED (NZ) 2007-05-18 — — WO claimed
WO-2006104397-A1 COPPER ANTAGONIST COMPOSITIONS PROTEMIX CORPORATION LIMITED (NZ) 2006-10-05 — — WO claimed
WO-2006104398-A1 COPPER ANTAGONIST COMPOSITIONS PROTEMIX CORPORATION LIMITED (NZ) 2006-10-05 — — WO claimed
WO-2006104399-A1 COPPER ANTAGONIST COMPOSITIONS PROTEMIX CORPORATION LIMITED (NZ) 2006-10-05 — — WO claimed
WO-2006104400-A1 COPPER ANTAGONIST COMPOSITIONS PROTEMIX CORPORATION LIMITED (NZ) 2006-10-05 — — WO claimed
WO-2006104401-A1 COPPER ANTAGONIST COMPOSITIONS PROTEMIX CORPORATION LIMITED (NZ) 2006-10-05 — — WO claimed
WO-2006104402-A1 COPPER ANTAGONIST COMPOSITIONS PROTEMIX CORPORATION LIMITED (NZ) 2006-10-05 — — WO claimed
WO-2006068516-A1 IMPLANTABLE MEDICAL DEVICES COATED WITH OR CONTAINING COPPER CHELATING COMPOUNDS PROTEMIX CORPORATION LIMITED (NZ) 2006-06-29 — — WO claimed
US-5691120-A PHOTOGRAPHY EASTMAN KODAK COMPANY (US) 1997-11-25 — — US claimed
US-5652085-A BLEACHING/FIXING PHOTOGRAPHIC FILMS EASTMAN KODAK COMPANY (US) 1997-07-29 — — US claimed
EP-4565559-A1 METHOD FOR TRIETHYLENETETRAMINE PURIFICATION Philera New Zealand Ltd. (NZ) 2025-06-11 — — EP disclosed
EP-0762203-A1 Succinic acid derivative degradable chelants, uses and compositions thereof EASTMAN KODAK COMPANY (US) 1997-03-12 — — EP disclosed
WO-1997008288-A1 SUCCINIC ACID DERIVATIVE DEGRADABLE CHELANTS, USES AND COMPOSITIONS THEREOF THE DOW CHEMICAL COMPANY (US) 1997-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160428-A1 TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS CS, GOT2, COX5B CA12 3267/4885CA6 2500/4885CA7 3626/4885
US-20130108709-A1 TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS TFAM, NDUFAB1, HSPA9 CA12 4517/4885CA6 3959/4885CA7 4359/4885
US-20090093506-A1 Copper antagonist compositions HMGCR, SLC10A1, PCSK9 CA12 2335/4885CA6 1195/4885CA7 1619/4885
US-20150196500-A1 Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits TFAM, NDUFAB1, HSPA9 CA12 4517/4885CA6 3959/4885CA7 4359/4885
US-20090093542-A1 Copper antagonist compositions ACE, CTRB2, AGTR2 CA12 964/4885CA6 356/4885CA7 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.